Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
CAMBRIDGE, Mass., Nov. 01, 2016 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its third quarter 2016 investor update conference call and live webcast scheduled for Thursday, November 10, 2016 at 8:30 a.m. EDT.
The live call may be accessed by dialing (877) 851-3834 for domestic callers or +1 (631) 291-4595 for international callers, and referencing conference ID number 11101029. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The Company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Investor Relations: Matt Osborne Head of Investor Relations & Corporate Communications 857-259-5353 [email protected] Media: Katie Engleman Pure Communications, Inc. 910-509-3977 [email protected]
